Additional file 1 of Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis

Additional file 1: Figure S1. Overall survival in patients with BCLC stage 0, A, B, and C disease by Kaplan-Meier analysis. Surgical resection (SR) resulted in significantly higher overall survival than radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) in BCLC stage 0 (P <0.05) (A). SR resulted in significantly higher overall survival than RFA and TACE in BCLC stage A (P <0.05) (B). SR resulted in significantly higher overall survival than RFA and TACE in BCLC stage A (P <0.05) (B). SR resulted in significantly higher overall survival than RFA, TACE, and other treatment in BCLC stage B (PP <0.05) (C). SR resulted in significantly higher overall survival than RFA, TACE, target therapy, radiotherapy (RTO), hepatic artery infusion therapy (HAIC), and best support care (BSC) in BCLC stage C (P <0.05) (D).附加文件1：图S1。针对巴塞罗那临床肝癌（Barcelona Clinic Liver Cancer, BCLC）分期0、A、B、C期患者的总生存期开展Kaplan-Meier分析（Kaplan-Meier analysis）。(A) 针对BCLC 0期患者，手术切除（Surgical resection, SR）的总生存期显著高于射频消融（radiofrequency ablation, RFA）与经动脉化疗栓塞术（transcatheter arterial chemoembolization, TACE）（P<0.05）。(B) 针对BCLC A期患者，手术切除（SR）的总生存期显著高于射频消融（RFA）与经动脉化疗栓塞术（TACE）（P<0.05）。(B) 针对BCLC A期患者，手术切除（SR）的总生存期显著高于射频消融（RFA）与经动脉化疗栓塞术（TACE）（P<0.05）。(C) 针对BCLC B期患者，手术切除（SR）的总生存期显著高于射频消融（RFA）、经动脉化疗栓塞术（TACE）及其他治疗手段（P<0.05）。(D) 针对BCLC C期患者，手术切除（SR）的总生存期显著高于射频消融（RFA）、经动脉化疗栓塞术（TACE）、靶向治疗、放射治疗（radiotherapy, RTO）、肝动脉灌注化疗（hepatic artery infusion therapy, HAIC）及最佳支持治疗（best support care, BSC）（P<0.05）。